X-linked lymphoproliferative syndrome
X-linked lymphoproliférative syndrome (Duncan syndrome) is a rare genetically primary immunodeficiency, typically characterized by occurrence of fatal EBV-induced mononucleosis and severe changes in immunologic studies. This article contains reference list and clinical case of the patient with XLP, who presented typical clinical picture and changes in immunologic studies. Mutation of SAP-gene did not revealed.
2. Mutation in a hypogammaglobulinemic male patient with a diagnosis of common variable immunodeficiency. Int J Hematol. 2003; 78: 45-7.
3. Cohen J.I. Epstein-Barr virus infection. The New England Journal of Medicine. - 2000. - Vol. 343. P. 481-492.
4. Coffey AJ, Brooksbank RA, Brandau O et al. Host response to EBV infection in X-linked lymphoproli¬férative disease results from mutations in an SH2-domain encoding gene. Nat Genet. Oct 1998; 20 (2): 129-35.
5. Conley M.E., Notarangelo L.D., Etzioni A. et al. Diagnostic Criteria for Primary Immunodeficiencies. ESID-Newsletter 10, Apr., 2000, p.l-19.
6. Eastwood D., Gilmour K.C., Nistala K. et al. Prevalence of SAP gene defects in small patients diagnosed with common variable immunodeficiency. Clin. Exp. Immunol. 2004, v.137, p. 584-588.
7. GasparHB, Sharifi R, Gilmour KC, Thrasher AJ. X-linked lymphoproliférative disease: clinical, diagnostic and molecular perspectives. Br J Haematol. 2002; 119: 585-95.
8. Gilmour K.C., Cranston T., Jones A. et al. // Diagnosis of X-linked lymphoproliferative disease by analysis of SLAM-assisted protein expression. Eur. J.Immunol. - 2000, - Vol. 30, p. 1691 - 1697
9. http: // bioinf.uta.fi/idr/Diag_XLP.html
10. http: // bioinf.uta.fi/xml/idr/ff/FF165.xml
12. Imashuku S. Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Crit Rev Oncol Hematol. 2002; 44: 259-72.
13. Lankester AC, Visser LF, Hartwig NG, Bredius RG, Gaspar HB, van der Burg M, van Tol MJ, Gross TG, Egeler RM. Allogeneic stem cell transplantation in X-linked lymphoproliférative disease: two cases in one family and a review of the literature. Bone Marrow Transplant. 2005; 36: 99-105.
14. Lewis J., Eiben L.J., Nelson D.L., Cohen J.I. Nichols K.E. et al. Distinct intraction of the X-linked lympho-proliferative syndrome gene product SAP with cytoplasmic domains of members of the CD2 receptor family. Clin. Immunol., 2001, Vol.100, P. 15-23.
15. Milone MC, Tsai DE, Hodinka RL et al. Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. Blood. Feb 1 2005; 105 (3): 994-6.
16. Nichols, K. E., Ma, C. S., Cannons, J. L., Schwartzberg, P. L.. & Tangye, S.G. Molecular and cellular pathogens of X-linked lymphoproliferative disease. Immunol. Rev. 203, 180-199 (2005)
17. None K.,. Gilmour K.C.,. Cranston T ... Davies E.G., Goldblatt D., Gaspar H.D. & Jones A.M.: X-linked lymphoproliférative disease: three atypical cases.Clin. Exp. Immunol. 126: 126-130, 2001
18. Pwtilo DT, Cassel CK, Yang JP, Harper R. X-linked recessive progressive combined variable immunode Xficiency (Duncan's disease). Lancet. Apr 26 1975; l (7913): 935-40,
19. Rigaud S, Fondanèche MC, Lambert N et al. XIAP deficiency in humans causes an X-linked lymphopro-liferative syndrome. Nature. Nov 2 2006; 444 (7115): 110-4.
This work is licensed under a Creative Commons Attribution 4.0 International License.